NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Forecast, Price & News

$2.76

-0.08 (-2.82%)

(As of 09/26/2023 ET)

Compare

Today's Range: $2.76
▼
$3.00
50-Day Range: $2.76
▼
$11.85
52-Week Range: $2.76
▼
$34.13

Volume: 497,073 shs
Average Volume: 1.39 million shs
Market Capitalization: $80.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.88

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.43 Rating Score
Upside/Downside: 765.0% Upside
$23.88 Price Target
Short Interest: Healthy
21.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.13
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.75) to ($2.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

117th out of 964 stocks

Pharmaceutical Preparations Industry

35th out of 441 stocks

4.2

Analyst's Opinion

Consensus Rating
BioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.88, BioXcel Therapeutics has a forecasted upside of 765.0% from its current price of $2.76.
Amount of Analyst Coverage
BioXcel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
21.80% of the float of BioXcel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
BioXcel Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioXcel Therapeutics has recently decreased by 34.81%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BioXcel Therapeutics does not currently pay a dividend.
Dividend Growth
BioXcel Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for BioXcel Therapeutics is -1.13.

2.0

News and Social Media Coverage

News Sentiment
BioXcel Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BioXcel Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 11 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.
MarketBeat Follows
8 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.86% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($5.75) to ($2.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioXcel Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioXcel Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioXcel Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Price History

30 days | 90 days | 365 days | Advanced Chart

BTAI Stock News Headlines

September 18, 2023 | americanbankingnews.com

Reviewing Vivesto (OTCMKTS:OASMY) and BioXcel Therapeutics (NASDAQ:BTAI)

September 8, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Bioxcel Therapeutics (BTAI), KalVista Pharmaceuticals (KALV)

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 5, 2023 | stockhouse.com

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

September 2, 2023 | prnewswire.com

BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

September 1, 2023 | technews.tmcnet.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

August 31, 2023 | markets.businessinsider.com

ROSEN, A Top Ranked Law Firm, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

August 29, 2023 | markets.businessinsider.com

ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

September 27, 2023 | Stansberry Research (Ad)

Bank Collapse Causes Gold Prices to Soar

Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.

August 28, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)

August 26, 2023 | prnewswire.com

BTAI CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

August 24, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. (BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

August 24, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

August 23, 2023 | benzinga.com

BTAI Investors Should Contact Robbins LLP About Participating in the Class Action Against BioXcel Therapeutics

August 23, 2023 | msn.com

Mizuho Reiterates BioXcel Therapeutics (BTAI) Neutral Recommendation

August 22, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Their Hold Rating for Bioxcel Therapeutics (BTAI)

August 19, 2023 | fool.com

BioXcel Therapeutics (NASDAQ: BTAI)

August 19, 2023 | prnewswire.com

BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

August 17, 2023 | prnewswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

August 17, 2023 | msn.com

Mizuho Downgrades BioXcel Therapeutics (BTAI)

August 17, 2023 | finance.yahoo.com

BTAI: Strategic Reprioritization Underway...

August 15, 2023 | msn.com

Mizuho cuts BioXcel to neutral, cites reduced expectations for lead drug

August 15, 2023 | finance.yahoo.com

Why BioXcel Therapeutics Stock Flopped Again Today

August 15, 2023 | uk.finance.yahoo.com

Further weakness as BioXcel Therapeutics (NASDAQ:BTAI) drops 42% this week, taking three-year losses to 90%

August 15, 2023 | msn.com

BioXcel Therapeutics to cut workforce 58%, stock falls 27%

August 15, 2023 | markets.businessinsider.com

Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy

August 15, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bioxcel Therapeutics (BTAI) and Roivant Sciences (ROIV)

See More Headlines

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Company Calendar

Last Earnings: 8/14/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BTAI
CUSIP: N/A
CIK: 1720893
Web: www.bioxceltherapeutics.com
Phone: (475) 238-6837
Fax: N/A
Employees: 183
Year Founded: 2017

Price Target and Rating

Average Stock Price Forecast: $23.88
High Stock Price Forecast: $40.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +765.0%
Consensus Rating: Hold
Rating Score (0-4): 2.43
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-165,760,000.00
Net Margins: -19,549.52%
Pretax Margin: -19,549.71%
Return on Equity: -309.06%
Return on Assets: -105.30%

Debt

Debt-to-Equity Ratio: 16.52
Current Ratio: 3.98
Quick Ratio: 3.92

Sales & Book Value

Annual Sales: $380,000.00
Price / Sales: 212.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.74 per share
Price / Book: 1.01

Miscellaneous

Outstanding Shares: 29,270,000
Free Float: 18,791,000
Market Cap: $80.79 million
Optionable: Not Optionable
Beta: 1.00

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Vimal D. Mehta Ph.D. (Age 62)
Founder, CEO, Pres, & Director
Comp: $1.76M

Mr. Javier Rodriguez (Age 51)
Sr. VP, Chief Legal Officer & Corp. Sec.
Comp: $638.88k

Mr. Matthew Wiley (Age 51)
Sr. VP & Chief Commercial Officer
Comp: $620.12k

Mr. Richard I. Steinhart MBA (Age 66)
Sr. VP & CFO

Dr. Frank D. Yocca Ph.D. (Age 67)
Sr. VP & Chief Scientific Officer

Dr. Vincent J. O'Neill B.Sc. (Age 54)
M.D., M.R.C.P., Sr. VP & Chief Medical Officer

Dr. Chetan D. Lathia Ph.D.
Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs

Dr. Robert Risinger M.D.
Chief Medical Officer - Neuroscience

Mr. Robert Scala (Age 54)
VP of Commercial Operations & Launch Planning

Dr. Friso Postma
Sr. Director of Neuroscience & Artificial intelligence

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings or view top-rated stocks.
What is BioXcel Therapeutics' stock price forecast for 2023?: 7 Wall Street research analysts have issued 12-month price targets for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $11.00 to $40.00. On average, they predict the company's share price to reach $23.88 in the next year. This suggests a possible upside of 765.0% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.
How have BTAI shares performed in 2023?: BioXcel Therapeutics' stock was trading at $21.48 at the beginning of the year. Since then, BTAI shares have decreased by 87.2% and is now trading at $2.76.
View the best growth stocks for 2023 here.
When is BioXcel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BTAI earnings forecast.
How were BioXcel Therapeutics' earnings last quarter?: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, August, 14th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.72) by $0.11. The business earned $0.46 million during the quarter, compared to analyst estimates of $0.42 million. BioXcel Therapeutics had a negative net margin of 19,549.52% and a negative trailing twelve-month return on equity of 309.06%. The business's revenue was up 45600.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.35) earnings per share.
What ETF holds BioXcel Therapeutics' stock ?: iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.
What other stocks do shareholders of BioXcel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?: (BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is BioXcel Therapeutics' stock symbol?: BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."
Who are BioXcel Therapeutics' major shareholders?: BioXcel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (7.11%), BlackRock Inc. (4.76%), Artemis Investment Management LLP (3.07%), Geode Capital Management LLC (1.39%), Northern Trust Corp (0.84%) and Point72 Asset Management L.P. (0.83%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill.
View institutional ownership trends.
How do I buy shares of BioXcel Therapeutics?: Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioXcel Therapeutics' stock price today?: One share of BTAI stock can currently be purchased for approximately $2.76.
How much money does BioXcel Therapeutics make?: BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $80.79 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis.
How many employees does BioXcel Therapeutics have?: The company employs 183 workers across the globe.
How can I contact BioXcel Therapeutics?: BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial